WuXi NextCODE, a global standard platform for genomic data, completed a $200m Series C financing.
The round was led by the Ireland Strategic Investment Fund (ISIF), with participation from existing shareholders Temasek, Yunfeng Capital and Sequoia Capital. ISIF was the lead shareholder in Genomics Medicine Ireland (GMI), which was recently acquired by WuXi NextCODE as its Irish subsidiary and business headquarters in Europe.
The company intends to use the funds to expand operations at GMI, and to accelerate the program to enroll and sequence the entire genome of some 400,000 people from across Ireland.
Led by Rob Brainin, CEO, WuXi NextCODE is an integrated global life sciences informatics company building the global standard platform for genomic data. Capabilities span study design, sequencing, secondary analysis, storage, interpretation, scalable analytics, and AI and deep learning – all backed by technology for organizing, mining and sharing genome sequence data.
With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; Reykjavik, Iceland; and Dublin, the company serves population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health.